Passage Bio Newsroom

Wedbush Maintains Passage Bio(PASG.US) With Buy Rating, Maintains Target Price $4

Moomoo NewsJan 10 10:33 ET · Ratings

Optimistic Outlook for Passage Bio: Buy Rating Justified by Promising Clinical Results and Extended Cash Runway

TipRanksJan 10 10:25 ET · Ratings

Passage Bio Restructures and Extends Cash Runway

TipRanksJan 10 07:29 ET

Express News | Passage Bio Says It Has Reviewed Its Operating Needs And Will Transition To An Outsourced Analytical Testing Model. This Transition, Coupled With An Associated Reduction In Workforce Of Approximately 55% And Reductions In Operating Expenses, Extends...

BenzingaJan 10 07:27 ET

Passage Bio Reported Updated Data From The Ongoing Phase 1/2 UpliFT-D Trial Of PBFT02 For Frontotemporal Dementia With Granulin Mutations

BenzingaJan 10 07:25 ET

Express News | Passage Bio : To Reduce Operating Costs and Better Align Its Workforce With Needs of Its Strategic Research and Development Strategy

ReutersJan 10 07:12 ET

Express News | Passage Bio Inc: To Cease Its Lab Operations at Its Approximately 62,000 Feet of Leased Laboratory Space in Hopewell, New Jersey

ReutersJan 10 07:11 ET

Express News | Passage Bio Inc: On Jan 8, Board Approved, and Management Began Implementing, Restructuring Plan

ReutersJan 10 07:11 ET

Express News | Passage Bio Inc - Extended Cash Runway Into 1Q 2027 by Reducing Operating Expenses

ReutersJan 10 07:02 ET

Express News | Passage Bio Inc - Expect to Report 12-Month Data From Dose 1 in 2H 2025

ReutersJan 10 07:02 ET

Express News | Passage Bio Inc - Pbft02 Shows Durable Csf Pgrn Levels and Reduced Plasma Nfl Levels

ReutersJan 10 07:02 ET

Express News | Passage Bio Announces Interim Data From Uplift-D Study in Ftd-Grn and Provides Business Updates

ReutersJan 10 07:00 ET

Will Passage Bio (NASDAQ:PASG) Spend Its Cash Wisely?

Yahoo FinanceDec 29, 2024 07:20 ET

Insider Sale: 10% Owner at $PASG (PASG) Sells 20,903 Shares

Quiver QuantitativeDec 6, 2024 19:15 ET

Yun Zhong, PhD, Joins Wedbush Securities as Senior Vice President, Equity Research, Biotechnology

BusinesswireDec 3, 2024 08:30 ET

Optimistic Buy Rating for Passage Bio Driven by Promising PBFT02 Therapy Potential and Accelerated Approval Pathway

TipRanksDec 2, 2024 07:46 ET

Passage Bio Assumed With an Outperform at Wedbush

Yahoo FinanceNov 30, 2024 06:55 ET

12 Health Care Stocks Moving In Friday's Pre-Market Session

BenzingaNov 29, 2024 16:06 ET

Passage Bio Coverage Assumed by Wedbush at Outperform

Dow JonesNov 29, 2024 10:39 ET

Passage Bio Price Target Announced at $4.00/Share by Wedbush

Dow JonesNov 29, 2024 10:39 ET · Ratings